Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

A Second Course of Radiotherapy in Patients with Recurrent Malignant Gliomas: Clinical Data on Re-irradiation, Prognostic Factors, and Usefulness of Digital Biomarkers.

Straube C, Kessel KA, Zimmer C, Schmidt-Graf F, Schlegel J, Gempt J, Meyer B, Combs SE.

Curr Treat Options Oncol. 2019 Jul 19;20(9):71. doi: 10.1007/s11864-019-0673-y. Review.

PMID:
31324990
2.
3.

Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas.

Combs SE, Bischof M, Welzel T, Hof H, Oertel S, Debus J, Schulz-Ertner D.

J Neurooncol. 2008 Sep;89(2):205-10. doi: 10.1007/s11060-008-9607-4. Epub 2008 May 7.

PMID:
18461281
4.

Re-Irradiation with Stereotactic Radiosurgery/Radiotherapy for Recurrent High-Grade Gliomas: Improved Survival in the Modern Era.

Gigliotti MJ, Hasan S, Karlovits SM, Ranjan T, Wegner RE.

Stereotact Funct Neurosurg. 2018;96(5):289-295. doi: 10.1159/000493545. Epub 2018 Nov 7.

PMID:
30404102
5.

Treatment of recurrent glioblastoma with stereotactic radiotherapy: long-term results of a mono-institutional trial.

Maranzano E, Anselmo P, Casale M, Trippa F, Carletti S, Principi M, Loreti F, Italiani M, Caserta C, Giorgi C.

Tumori. 2011 Jan-Feb;97(1):56-61.

PMID:
21528665
6.
7.

Multidisciplinary management of adult low grade gliomas.

Mariş D, Nica D, Mohan D, Moisa H, Ciurea AV.

Chirurgia (Bucur). 2014 Sep-Oct;109(5):590-9.

8.

Randomised phase I/II study to evaluate carbon ion radiotherapy versus fractionated stereotactic radiotherapy in patients with recurrent or progressive gliomas: the CINDERELLA trial.

Combs SE, Burkholder I, Edler L, Rieken S, Habermehl D, Jäkel O, Haberer T, Haselmann R, Unterberg A, Wick W, Debus J.

BMC Cancer. 2010 Oct 6;10:533. doi: 10.1186/1471-2407-10-533.

9.

Generation and validation of a prognostic score to predict outcome after re-irradiation of recurrent glioma.

Combs SE, Edler L, Rausch R, Welzel T, Wick W, Debus J.

Acta Oncol. 2013 Jan;52(1):147-52. doi: 10.3109/0284186X.2012.692882. Epub 2012 Jun 11.

PMID:
22686472
10.

Re-irradiation for recurrent high-grade gliomas: a systematic review and analysis of treatment technique with respect to survival and risk of radionecrosis.

Shanker M, Chua B, Bettington C, Foote MC, Pinkham MB.

Neurooncol Pract. 2019 Mar;6(2):144-155. doi: 10.1093/nop/npy019. Epub 2018 Jun 14.

PMID:
31386038
11.

Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter?

Palmer JD, Bhamidipati D, Song A, Eldredge-Hindy HB, Siglin J, Dan TD, Champ CE, Zhang I, Bar-Ad V, Kim L, Glass J, Evans JJ, Andrews DW, Werner-Wasik M, Shi W.

J Neurooncol. 2018 Dec;140(3):623-628. doi: 10.1007/s11060-018-2989-z. Epub 2018 Sep 4.

PMID:
30182159
12.

Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.

Cuneo KC, Vredenburgh JJ, Sampson JH, Reardon DA, Desjardins A, Peters KB, Friedman HS, Willett CG, Kirkpatrick JP.

Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):2018-24. doi: 10.1016/j.ijrobp.2010.12.074. Epub 2011 Apr 12.

13.

Feasibility and outcome of re-irradiation in the treatment of multiply recurrent pituitary adenomas.

Verma J, McCutcheon IE, Waguespack SG, Mahajan A.

Pituitary. 2014 Dec;17(6):539-45. doi: 10.1007/s11102-013-0541-x.

PMID:
24272035
14.

Factors improving the outcome of patients re-irradiated with intensity-modulated radiotherapy (IMRT) for relapse or new head and neck cancer developed in irradiated areas.

Ohnleiter T, Antoni D, Lefebvre F, Truntzer P, Schultz P, Burgy M, Borel C, Noël G.

Chin Clin Oncol. 2018 Dec;7(6):60. doi: 10.21037/cco.2018.06.07. Epub 2018 Jun 27.

15.

Adjuvant stereotactic fractionated radiotherapy to the resection cavity in recurrent glioblastoma - the GlioCave study (NOA 17 - ARO 2016/3 - DKTK ROG trial).

Straube C, Scherb H, Gempt J, Kirschke J, Zimmer C, Schmidt-Graf F, Meyer B, Combs SE.

BMC Cancer. 2018 Jan 3;18(1):15. doi: 10.1186/s12885-017-3928-7.

16.

Salvage Fractionated Stereotactic Radiotherapy with or without Chemotherapy and Immunotherapy for Recurrent Glioblastoma Multiforme: A Single Institution Experience.

Hasan S, Chen E, Lanciano R, Yang J, Hanlon A, Lamond J, Arrigo S, Ding W, Mikhail M, Ghaneie A, Brady L.

Front Oncol. 2015 May 15;5:106. doi: 10.3389/fonc.2015.00106. eCollection 2015.

17.

Anaplastic glioma.

Paleologos NA, Merrell RT.

Curr Treat Options Neurol. 2012 Aug;14(4):381-90. doi: 10.1007/s11940-012-0177-6.

PMID:
22665140
18.

The role of salvage reirradiation for malignant gliomas that progress on bevacizumab.

Torcuator RG, Thind R, Patel M, Mohan YS, Anderson J, Doyle T, Ryu S, Jain R, Schultz L, Rosenblum M, Mikkelsen T.

J Neurooncol. 2010 May;97(3):401-7. doi: 10.1007/s11060-009-0034-y. Epub 2009 Oct 17.

PMID:
19838627
19.

Moving Second Courses of Radiotherapy Forward: Early Re-Irradiation After Surgical Resection for Recurrent Gliomas Improves Efficacy With Excellent Tolerability.

Combs SE, Kessel KA, Hesse J, Straube C, Zimmer C, Schmidt-Graf F, Schlegel J, Gempt J, Meyer B.

Neurosurgery. 2018 Dec 1;83(6):1241-1248. doi: 10.1093/neuros/nyx629.

PMID:
29462372
20.

Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas.

Cho KH, Hall WA, Gerbi BJ, Higgins PD, McGuire WA, Clark HB.

Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1133-41.

PMID:
10613305

Supplemental Content

Support Center